r.petrov

TL2 · Tilburg

Contributes reviews on supplier material. Based in Tilburg.

Joined 18 August 2025 · last posted 6d

75 posts, newest first. Showing up to 150.

Second pass at: Which categories are strict and which are relaxed, honestly Replied, post #98 · Start Here › Welcome · 22 Jul 2026 · 5 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
Aggregate verification data across the directory, with caveats Replied, post #63 · Sourcing › Independent verification · 22 Jul 2026 · 5 likes Post #60 is the version of this I will quote in future. One addition. Interpreting a result: a purity figure is one measurement on one vial on one day. Agreement across…
Here for the analytics and not much else Replied, post #71 · Lounge › Introductions · 22 Jul 2026 · 25 likes No judgment: people come to this community from all backgrounds and with all motivations. Introductions are for getting to know each other, not for evaluation. I have…
Ultrasound and skinfolds: operator dependence in practice Replied, post #67 · Outcomes › Body composition · 20 Jul 2026 · 7 likes Neither method is capable of detecting the month-to-month changes that people report detecting month to month.
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #78 · Evidence › Journal club · 17 Jul 2026 · 24 likes If you are new and reading this thread for the answer to SUSTAIN 6: the answer is conditional, the conditions are in the third reply, and the rest of the thread is…
Publication patterns in the BPC-157 literature, examined Replied, post #36 · Compounds › Repair & healing peptides · 15 Jul 2026 · 0 likes BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth…
Alcohol: what is documented and what is folklore Replied, post #102 · Practice › Interactions · 9 Jul 2026 · 28 likes Alcohol looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
Request: a per-category review queue Replied, post #51 · Meta › Feature requests · 21 Jun 2026 · 0 likes Then the honest version is a comparison of the record shapes rather than the scores. How many results, over how long, from which services. That I would use.
What would change my mind about repair peptides: a specific answer Replied, post #7 · Compounds › Repair & healing peptides · 7 Jun 2026 · 14 likes The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well…
Official shortage notices and what they authorise Replied, post #59 · Access › Shortages · 20 May 2026 · 7 likes Worth separating two things that post #57 runs together. On official shortage notices I would separate what is worth knowing from what is worth acting on. The first…
A parcel stationary at a customs facility for nine days Replied, post #61 · Sourcing › Logistics · 19 May 2026 · 2 likes Parcel stationary: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to…
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #51 · Evidence › Preprints · 12 May 2026 · 0 likes Retractions and corrections do not propagate well from preprint servers. A citation that was fine when made can quietly become wrong. Not a strong opinion, just a…
Alcohol: what is documented and what is folklore Replied, post #2 · Practice › Interactions · 3 May 2026 · 24 likes Second-hand on alcohol, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
Request: show the solution author in the topic list — what changed since Replied, post #65 · Meta › Feature requests · 3 May 2026 · 0 likes Request with a caveat attached: a compare view for two vendor pages side by side. The caveat is that it would encourage exactly the ranking-by-number reading the pages…
GLP-1 receptor distribution: central and peripheral Replied, post #30 · Pharmacology › Receptor biology · 11 Apr 2026 · 2 likes Everything in post #28 holds. The case it does not cover is the one I have. GIP receptor signalling: the glucose-dependent insulinotropic peptide receptor (GIP) is…
Spike-and-recover accuracy for a peptide assay Replied, post #99 · Analytics › Method validation · 10 Apr 2026 · 7 likes Speaking only to spike-and-recover accuracy as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread…
Coming back to: What the published dose-response for semaglutide actually looks like… Replied, post #16 · Compounds › Semaglutide · 6 Apr 2026 · 11 likes Post #14 and I disagree about the size of the effect, not about the direction. A note on scope: what I am saying about published dose-response for semaglutide applies…
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #112 · Pharmacology › Pharmacokinetics · 22 Mar 2026 · 0 likes Confirming post #111 from a second method, which matters more than confirming it from a second person. Renal clearance: these compounds are cleared partly via the…
Nausea profile of amylin analogues compared with GLP-1 agonists Replied, post #57 · Compounds › Cagrilintide & amylin analogues · 11 Mar 2026 · 0 likes What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs…
Micro-titration: a disputed topic, argued properly — one year on Replied, post #12 · Practice › Dosing & titration · 10 Mar 2026 · 0 likes Nothing here is medical advice, and a titration question is one of the few where a prescriber can genuinely answer in a minute what a thread will take a week to circle.…
[2026 update] A rising related-substance total over six months: degradation or method… Replied, post #65 · Analytics › Impurities & related substances · 19 Feb 2026 · 0 likes Post #64 describes the usual case. This is about the unusual one. The most useful thing anyone has posted about rising related-substance in this category was a table of…
Micro-titration: a disputed topic, argued properly Replied, post #29 · Practice › Dosing & titration · 1 Feb 2026 · 0 likes Where I part company with post #26, and it is a narrow parting. Micro-titration sits at the boundary between what this community can usefully discuss and what it…
[2026 update] Storing lyophilised material long term: what governs the shelf life Replied, post #52 · Practice › Storage & stability · 17 Jan 2026 · 5 likes Answering the question post #50 raises rather than the one it answers. An honest declaration on Storing lyophilised material long term: I have a prior here and it is…
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #48 · Sourcing › Red flags · 13 Jan 2026 · 19 likes Claims of pharmaceutical-grade status for research-use-only material are a labelling problem and are common enough to be worth expecting rather than reacting to.
Second pass at: Programming during a large energy deficit Replied, post #94 · Nutrition & Training › Resistance training · 23 Nov 2025 · 17 likes Post #92 answers the question as asked. The question underneath it is different. A resistance stimulus during a deficit is the other half of the lean-tissue argument,…
Pooling trials with different estimands — what changed since Replied, post #55 · Evidence › Meta-analyses · 23 Nov 2025 · 26 likes The arithmetic in post #53 is right; the assumption feeding it is the part to check. Pooled estimates and heterogeneity: when trials differ in population, duration, or…
Lurking for two months before posting: was that the right call? Replied, post #10 · Start Here › Welcome · 17 Nov 2025 · 11 likes Worth knowing early: the archive is not retrospectively corrected. A topic from two years ago was accurate when written and may not be now. Every post carries its date…
Robustness: the parameters worth deliberately varying Replied, post #4 · Analytics › Method validation · 16 Nov 2025 · 0 likes This follows the opening post rather than contradicting it. System suitability is the ongoing evidence that a validated method is still performing. Validation is done…
Second pass at: What "verified" means on our vendor pages, stated narrowly Replied, post #35 · Sourcing › Vendor reports · 15 Nov 2025 · 3 likes Reports of ordinary results are more valuable than reports of remarkable ones, precisely because only the remarkable ones get posted elsewhere.
Revisiting: Aggregates and why a purity assay may miss them entirely Replied, post #8 · Analytics › Impurities & related substances · 14 Nov 2025 · 28 likes Genuine question rather than a rhetorical one: has anyone here actually observed Aggregates, as opposed to read about it? The thread is long and I cannot tell.
An inter-laboratory comparison on one lot, tabulated — what changed since Replied, post #15 · Analytics › Method validation · 13 Nov 2025 · 0 likes Bookmarking this. I will come back when I have something worth adding.
Cross-border purchase rules within the EU Replied, post #35 · Regional › European Union · 7 Nov 2025 · 8 likes Coming back to post #33, because the follow-up matters more than the original answer. I read the earlier replies on cross-border purchase rules within twice before…
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #9 · Pharmacology › Pharmacokinetics · 26 Oct 2025 · 0 likes Renal clearance: these compounds are cleared partly via the kidney. In severe renal impairment, clearance is slowed and accumulation risk is higher. Dose adjustments…
Where to report an adverse event officially, by region — a second dataset Replied, post #52 · Safety › Adverse events · 24 Oct 2025 · 0 likes Pancreatitis is a genuine serious adverse event to know: severe epigastric pain, back pain, elevated lipase (≥3× upper limit of normal). If this constellation appears,…
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one Replied, post #12 · Compounds › Oral incretins · 20 Oct 2025 · 8 likes Taking the oral product with more water than instructed reduces absorption rather than helping it. That is counter-intuitive and it is one of the few dosing…
Payment mechanics and the recovery options that do not exist Replied, post #15 · Sourcing › Payments · 19 Oct 2025 · 9 likes This follows post #14 rather than contradicting it. Minimum order quantities are a legitimate commercial constraint and are worth asking about before designing an order…
Citing a preprint in a maintained document: our rule and its reasoning — does this still… Replied, post #74 · Evidence › Preprints · 1 Oct 2025 · 18 likes If you cite a preprint in a maintained document here, the convention is to label it in the sentence and to note the check date. The document review will catch the update.
Temperature loggers worth the money — the long version Replied, post #47 · Devices › Cold chain · 27 Sep 2025 · 1 like One caution on Temperature loggers worth the money: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work…
What a 2 ppm match establishes, and what it does not Replied, post #51 · Analytics › Mass spectrometry · 16 Sep 2025 · 8 likes Reframing 2 ppm match slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how…
How to read a forest plot, properly, from scratch Replied, post #27 · Evidence › Trials · 13 Sep 2025 · 10 likes A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened…
Second pass at: Why this subcategory is stricter about sourcing than most Replied, post #126 · Compounds › Secretagogues & GH axis · 2 Sep 2025 · 1 like Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in…
Second pass at: The mass-error checker and its intended scope Replied, post #7 · marked as the solution · Data & Tools › Calculators · 28 Aug 2025 · 7 likes My understanding of mass-error checker is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
Managing an unplanned gap in supply — what changed since Replied, post #42 · Access › Shortages · 20 Aug 2025 · 5 likes Checked the Managing an unplanned gap claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the…
Why oral semaglutide needs an absorption enhancer at all Replied, post #20 · Compounds › Oral incretins · 22 Jul 2025 · 22 likes I read post #17 twice before replying, because I had assumed the opposite. Research-use-only oral material is not a licensed tablet and there is no reason to assume it…
Revisiting: Completing a dose with a second syringe, and the dead-volume arithmetic Replied, post #19 · Practice › Administration · 20 Jul 2025 · 7 likes I came in to disagree and I am leaving without a disagreement.
Request: a diff view for wiki revisions — the long version Replied, post #18 · Meta › Feature requests · 12 Jul 2025 · 0 likes Post #17 is right about the mechanism and I think understates the practical bit. The useful distinction on diff view for wiki revisions is between what was measured and…
Sequence verification for an obscure compound: how it is done Replied, post #79 · Compounds › Other compounds · 1 Jul 2025 · 2 likes Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its…
Reading a chromatogram someone posted without axes Replied, post #51 · Analytics › HPLC & UHPLC · 27 Jun 2025 · 22 likes My understanding of reading a chromatogram is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
[2026 update] Clearance pathways and what renal impairment changes Replied, post #69 · Pharmacology › Pharmacokinetics · 27 Jun 2025 · 3 likes Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein.…
Reading a supplier's product description as a marketing document Replied, post #33 · Compounds › Other compounds · 14 Jun 2025 · 27 likes I read post #29 twice before replying, because I had assumed the opposite. Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical…
Hepatic steatosis: what the MASH trial evidence supports Replied, post #53 · Clinical › Comorbidities · 31 May 2025 · 18 likes Seconded. It reads as careful rather than confident, which is the right register.
Follow-up: The lowest dose that does anything: is that a real question? Replied, post #16 · Practice › Dosing & titration · 26 May 2025 · 0 likes Nothing to add, except that this is the answer I would give if asked.
Adjudicated events and why the definition matters — the long version Replied, post #147 · Evidence › Trials · 10 May 2025 · 8 likes Picking up post #144: that is the part I would want checked first. Worth separating Adjudicated events as a question about the compound from Adjudicated events as a…
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ Replied, post #19 · Sourcing › Independent verification · 27 Apr 2025 · 0 likes I would be cautious about generalising from the Janoshik example above. It is a good example. It is one example.
Reading a trial's population section before its results — does this still hold? Replied, post #41 · Evidence › Trials · 26 Apr 2025 · 2 likes A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened…
Coming back to: Sample size calculations, read backwards from the published number Replied, post #16 · Evidence › Trials · 23 Apr 2025 · 5 likes Post #15 is the version of this I will quote in future. One addition. My experience of Sample size calculations contradicts the reply above. I am posting it as a data…
Comparators chosen for regulatory reasons rather than clinical ones — one year on Replied, post #7 · Evidence › Trials · 6 Apr 2025 · 5 likes Noted, and I have changed what I was going to do on the strength of it.
Delayed gastric emptying and oral medication absorption: which drugs matter Replied, post #31 · Practice › Interactions · 30 Mar 2025 · 19 likes Where I part company with post #29, and it is a narrow parting. The bit of delayed gastric emptying and oral that nobody enjoys is that the answer changes depending on…
Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #45 · Evidence › Journal club · 15 Mar 2025 · 0 likes One more thing on SURMOUNT-OSA that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent…
Adjudicated events and why the definition matters — the long version Replied, post #35 · Evidence › Trials · 6 Mar 2025 · 0 likes Surrogate endpoints: an endpoint that is not the outcome that matters but is measured as a stand-in. HbA1c is a surrogate for long-term glucose control and the…
Consistent declarations and why they matter more than clever ones Replied, post #133 · Sourcing › Logistics · 6 Mar 2025 · 26 likes If someone has run consistent declarations properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
Second pass at: Gauge and length selection for subcutaneous injection Replied, post #21 · Devices › Syringes & needles · 20 Jan 2025 · 5 likes Sharps containers are a legal requirement for disposal in several jurisdictions and a sensible precaution everywhere. A rigid sealed container is the minimum.
[2026 update] Lipid changes during rapid weight loss: the expected trajectory Replied, post #14 · Clinical › Bloodwork · 10 Jan 2025 · 32 likes Worth separating two things that post #12 runs together. Time of day: some biomarkers vary across the day. Cortisol in the morning differs from cortisol in the evening.…
What changed in 2026, by region Replied, post #62 · Access › International · 7 Jan 2025 · 6 likes Where a compound is approved under a different trade name in another market, searching the local name finds documents the English name does not.
Pancreatitis history and the risk calculus — a second dataset Replied, post #16 · Safety › Contraindications · 12 Dec 2024 · 12 likes On post #12 — agreed on the reasoning, with one qualification. Disordered eating history: appetite suppression can trigger relapse in people with history of anorexia,…
Second pass at: Choosing a concentration on purpose rather than by accident Replied, post #38 · Practice › Reconstitution · 6 Dec 2024 · 3 likes Do not shake. Swirl, or leave it. Vigorous agitation introduces air and shear, and neither helps a peptide go into solution any faster than patience does. It is the…
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Replied, post #123 · Compounds › Other compounds · 17 Nov 2024 · 0 likes Where I part company with post #119, and it is a narrow parting. On Melanocortin agonists I would separate what is worth knowing from what is worth acting on. The first…
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #19 · Compounds › Repair & healing peptides · 9 Nov 2024 · 28 likes Coming back to post #16, because the follow-up matters more than the original answer. I would keep reading a preclinical wound-healing model and the decision it usually…
Second pass at: Buffers, pH and why a formulation is a formulation Replied, post #2 · Pharmacology › Formulation chemistry · 17 Oct 2024 · 11 likes I have three months of notes on Buffers and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion…
Follow-up: A site rotation scheme that is easy enough to actually follow Replied, post #81 · Practice › Administration · 5 Oct 2024 · 0 likes If you have to inject at a different time of day than usual, that is a much smaller perturbation than it feels for a weekly compound with a week-long half-life. Caveat:…
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Replied, post #10 · Compounds › Other compounds · 20 Sep 2024 · 0 likes Coming back to post #6, because the follow-up matters more than the original answer. Genuine question rather than a rhetorical one: has anyone here actually observed…
Second pass at: Sodium, potassium and magnesium when intake drops Replied, post #47 · Nutrition & Training › Hydration & electrolytes · 18 Aug 2024 · 1 like Fluid intake: baseline needs increase with gastrointestinal effects and exercise. Thirst is not a reliable guide during appetite suppression. Drinking regularly (not…
Guidelines revision: what changed and why Replied, post #19 · Meta › Announcements · 25 Jul 2024 · 4 likes Adding thanks rather than a view. I do not have a view worth the space.
Journal club: FLOW and the renal composite, component by component Replied, post #53 · Evidence › Journal club · 14 Jul 2024 · 8 likes Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later. This is the…
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #127 · Practice › Dosing & titration · 10 Jul 2024 · 0 likes The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The…